| 摘要 |
The invention comprises: N-(5,6,7,8-tetrahydro-1-naphthyl) anthranilic and N-(4-indanyl) anthranilic acids and salts thereof; their preparation by (a) condensing a compound of the formula <FORM:0930477/IV(a)/1> with a compound of the formula <FORM:0930477/IV(a)/2> (wherein M is a hydrogen or alkali metal atom, Y and Z are different, one being an amino group and the other a halogen atom, and c is 3 or 4), or (b) hydrolysing a compound of the formula <FORM:0930477/IV(a)/3> (wherein R is a hydrogen atom or a C1-4 alkyl group, and Ph is a phenyl group optionally substituted by halogen or nitro, C1-4 alkyl or C1-4 alkoxy radicals), with optional conversion of the product to the free acid or a salt in each case; and pharmaceutical preparations containing a compound of the invention in association with a carrier or diluent. The starting materials for process (b) may be prepared by reacting a benzimidoyl chloride of the formula <FORM:0930477/IV(a)/4> with a salicylate of the formula <FORM:0930477/IV(a)/5> (wherein R1 is a C1-4 alkyl group), or an alkali metal salt thereof, to give an imidoester of the formula <FORM:0930477/IV(a)/6> and heating the imidoester to cause intramolecular rearrangement, with optional mild hydrolysis. 5-Aminotetralin is prepared by hydrolysis of its N-acetyl derivative. N-(5,6,7,8-tetrahydro-1-naphthyl) benzimidoyl chloride is prepared by heating N-benzoyl-5-aminotetralin with phosphorus pentachloride in benzene. The compounds of the invention possess antipyretic and anti-inflammatory activity and mitigate the symptoms of rheumatic, arthritic and other inflammatory conditions, and may be administered orally in the form of pharmaceutical preparations (e.g. tablets, capsules, powders and aqueous and nonaqueous suspensions and solutions) containing them in association with a solid or liquid carrier or diluent.
|
